Neola Medical Strengthens Global IP Portfolio with New Patents Granted in both the U.S. and China for Medical Device Neola®

Neola Medical AB (publ) has been granted patents in both the U.S. and China for a technical method that improve the accuracy of continuous lung monitoring with the company’s medical device, Neola®. The new patent grants represent a key milestone in the company’s global IP strategy and further strengthen its competitive position ahead of market expansion. Together with previously granted patent in Europe, the company now holds IP coverage for Neola Medical’s proprietary innovation for offset compensation across all target markets.

“Patent protection in both the U.S. and China secures a key part of our medical device in two of the world’s most significant healthcare markets. It supports our pathway toward U.S. market authorization and long-term global commercialization,” says CEO Hanna Sjöström.

About the patent
The granted patents represent a central element of Neola Medical’s patent family “A method and device for offset compensation,” protecting the company’s innovation for compensating background signals and thereby enhancing the accuracy of continuous lung monitoring in preterm born babies.

Datum 2025-10-16, kl 08:00
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!